Novo Nordisk A/S/€NOVOB
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Bagsværd, Denmark, that operates in the pharmaceutical industry with a primary focus on diabetes care. The company develops, manufactures, and markets pharmaceutical products and services, with significant emphasis on insulin and GLP-1 therapy for diabetes management. Novo Nordisk is also involved in the treatment of obesity, rare blood and endocrine disorders, and growth hormone therapy. The company was founded in 1923 and has a substantial international presence, offering products in more than 170 countries. Novo Nordisk's strategic strengths include its extensive research and development capabilities, a strong product pipeline, and a deep commitment to innovation in chronic disease management.
Ticker
€NOVOB
Sector
Primary listing
XGAT
Employees
78,387
Headquarters
Bagsvaerd, Denmark
Website
Novo Nordisk A/S Metrics
BasicAdvanced
€197B
13.38
€3.34
0.27
€1.56
3.49%
Price and volume
Market cap
€197B
Beta
0.27
52-week high
€108.86
52-week low
€38.56
Average daily volume
339K
Dividend rate
€1.56
Financial strength
Current ratio
0.784
Quick ratio
0.505
Long term debt to equity
51.947
Total debt to equity
59.065
Dividend payout ratio (TTM)
45.63%
Interest coverage (TTM)
17.27%
Profitability
EBITDA (TTM)
21,323.455
Gross margin (TTM)
84.26%
Net profit margin (TTM)
35.61%
Operating margin (TTM)
47.65%
Effective tax rate (TTM)
21.10%
Revenue per employee (TTM)
€532,880
Management effectiveness
Return on assets (TTM)
21.82%
Return on equity (TTM)
79.17%
Valuation
Price to earnings (TTM)
13.379
Price to revenue (TTM)
4.76
Price to book
8.76
Price to tangible book (TTM)
24.45
Price to free cash flow (TTM)
24.101
Free cash flow yield (TTM)
4.15%
Free cash flow per share (TTM)
1.855
Dividend yield (TTM)
3.49%
Growth
Revenue change (TTM)
20.90%
Earnings per share change (TTM)
24.26%
3-year revenue growth (CAGR)
25.65%
10-year revenue growth (CAGR)
12.15%
3-year earnings per share growth (CAGR)
31.20%
10-year earnings per share growth (CAGR)
15.33%
3-year dividend per share growth (CAGR)
27.85%
10-year dividend per share growth (CAGR)
16.64%
Bulls say / Bears say
Novo Nordisk’s semaglutide (Wegovy/Ozempic) has been recommended as a first-line obesity treatment by the European Association for the Study of Obesity, underscoring the company’s clinical leadership in GLP-1 therapies (Reuters).
The company is investing $1.09 billion to expand its Minas Gerais, Brazil facility, significantly increasing production capacity for injectable drugs like Ozempic and Wegovy to support global supply amid robust demand (Reuters).
Despite revising its 2025 outlook, Novo reported Q1 operating profit of DKK 38.79 billion, up 22 percent year-over-year and above analysts’ forecasts, highlighting resilient profitability amid market headwinds (Reuters).
A Reuters Breakingviews analysis warns that intensifying competition from over 140 obesity drugs in development could halve the combined market share of incumbent GLP-1 leaders, pressuring Novo’s valuation and growth prospects (Reuters).
The U.S. government’s 100 percent tariff on branded drug imports from October 1 threatens significant cost increases for Novo’s key products Ozempic and Wegovy, raising margin risks in its largest market (Reuters).
Novo Nordisk’s share of the European insulin market has fallen to roughly 45 percent, down from previous highs, as pricing pressure and competitor promotions erode its leading position outside North America (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novo Nordisk A/S stock?
Novo Nordisk A/S (NOVOB) has a market cap of €197B as of October 29, 2025.
What is the P/E ratio for Novo Nordisk A/S stock?
The price to earnings (P/E) ratio for Novo Nordisk A/S (NOVOB) stock is 13.38 as of October 29, 2025.
Does Novo Nordisk A/S stock pay dividends?
Yes, the Novo Nordisk A/S (NOVOB) stock pays dividends to shareholders. As of October 29, 2025, the dividend rate is €1.56116 and the yield is 3.49%. Novo Nordisk A/S has a payout ratio of 45.63% on a trailing twelve-month basis.
When is the next Novo Nordisk A/S dividend payment date?
The next Novo Nordisk A/S (NOVOB) dividend payment date is unconfirmed.
What is the beta indicator for Novo Nordisk A/S?
Novo Nordisk A/S (NOVOB) has a beta rating of 0.27. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.